BioMarin Pharmaceuticals Inc (BMRN) Stock Price

BMRNStock
$66.12+11.08%52W
Market Cap$12.80B
P/E38.27x
PEG Ratio0.52
Div yield
Beta0.21

BMRN Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-6.01%
Price vs S&P 500 (4W)1.78%
PEG Ratio0.52
VGM Score47.99
P/E Ratio (Annual)38.27x

BMRN Earnings Surprise History

Q2 251.44est. 1.03
Q3 250.12est. 0.34
Q4 250.46est. 0.56
Q1 260.76est. 0.91
Q2 261.20est. 0.95

BMRN Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.13
4.12
4.12
4.09

Industry Peers — Pharmaceuticals(571)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
BMRNBioMarin Pharmaceuticals Inc
CCC$66.12
LLYEli Lilly & Co.DBB$1233.66
JNJJohnson & JohnsonDCB$273.14
ABBVABBVIE INC.DCB$265.79
MRKMerck & Co., Inc.DCA$156.45
NVSNovartis AGCCC$159.98
AZNAstraZeneca PLCCBC$169.66
NVONovo-Nordisk A/SBCC$48.66
ABTAbbott LaboratoriesCCB$116.13
PFEPfizer Inc.CDC$28.57
VRTXVertex Pharmaceuticals IncDCB$552.85

About BioMarin Pharmaceuticals Inc

BioMarin Pharmaceutical develops therapies for rare genetic diseases, specializing in enzyme replacement and gene therapies. The company has eight approved treatments for achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. An early-stage pipeline targets additional skeletal conditions and enzyme-based therapies.